Publication: Predictors of sick leave days in patients affected by major depressive disorder receiving antidepressant treatment in general practice setting in Germany
| dc.contributor.author | Kasper, Siegfried | |
| dc.contributor.author | Bonelli, Annalisa | |
| dc.contributor.author | Cattaneo, Agnese | |
| dc.contributor.author | Comandini, Alessandro | |
| dc.contributor.author | Di Dato, Giorgio | |
| dc.contributor.author | Heiman, Franca | |
| dc.contributor.author | Pegoraro, Valeria | |
| dc.contributor.author | Palao, Diego | |
| dc.contributor.author | Roca, Miquel | |
| dc.contributor.author | Volz, Hans-Peter | |
| dc.date.accessioned | 2024-09-18T06:45:04Z | |
| dc.date.available | 2024-09-18T06:45:04Z | |
| dc.date.issued | 2021-11-02 | |
| dc.description.abstract | Objective: To identify sick leave days (SLD) predictors after starting antidepressant (AD) treatment in patients affected by major depressive disorder (MDD), managed by general practitioners, with a focus on different AD therapeutic approaches. Methods: Retrospective study on German IQVIA(R) Disease Analyser database. 19-64 year old MDD patients initiating AD treatment between July-2016 and June-2018 were grouped by therapeutic approach (AD monotherapy versus combination/switch/add-on). Data were analysed descriptively by AD therapeutic approach, while a zero-inflated Poisson (ZIP) multiple regression model was run to evaluate SLD predictors. Results: 8,891 patients met inclusion criteria (monotherapy: 66%; combination/switch/add-on: 34%). All covariates had an influence on SLD after AD treatment initiation. Focussing on variables that physicians may more easily intervene to improve outcomes, it was found that the expected SLD number of combination/switch/add-on patients was 1.6 times that of monotherapy patients, and the expected SLD number of patients diagnosed with MDD before the decision to start AD treatment was 1.2 times that of patients not diagnosed with MDD. Conclusions: A patient tailored approach in the selection of AD treatment at the time of MDD diagnosis may improve functional recovery and help to reduce the socio-economic burden of the disease. | en |
| dc.description.sponsorship | This study was funded by Angelini Pharma S.p.A. Annalisa Bonelli, Agnese Cattaneo, Alessandro Comandini, and Giorgio Di Dato are employees of Angelini Pharma S.p.A. Franca Heiman and Valeria Pegoraro are employees of IQVIA. Siegfried Kasper received grants/research support, consulting fees and/or honoraria within the last three years from Angelini, AOP Orphan Pharmaceuticals AG, Celgene GmbH, Janssen-Cilag Pharma GmbH, KRKA-Pharma, Lundbeck A/S, Mundipharma, Neuraxpharm, Pfizer, Sage, Sanofi, Schwabe, Servier, Shire, Sumitomo Dainippon Pharma Co. Ltd., Sun Pharmaceutical Industries Ltd. and Takeda. Miquel Roca received research funds or grants from Angelini, Janssen, Lundbeck and Pfizer. Hans-Peter Volz received grants/research support, consulting fees and/or honoraria within the last three years from Lundbeck, Pfizer, Schwabe, Bayer, Janssen-Cilag, Neuraxpharm, Recordati, AstraZeneca, Gilead, Servier, Otsuka, Recordati. Diego Palao has received grants and also served as consultant or advisor for Angelini, Janssen, Lundbeck and Servier. | es_ES |
| dc.format.number | 4 | es_ES |
| dc.format.page | 393-402 | es_ES |
| dc.format.volume | 25 | es_ES |
| dc.identifier.citation | Kasper S, Bonelli A, Cattaneo A, Comandini A, Di Dato G, Heiman F, et al. Predictors of sick leave days in patients affected by major depressive disorder receiving antidepressant treatment in general practice setting in Germany. Int J Psychiat Clin. 2021 Nov 2;25(4):393-402. | en |
| dc.identifier.doi | 10.1080/13651501.2021.1972120 | |
| dc.identifier.e-issn | 1471-1788 | es_ES |
| dc.identifier.issn | 1365-1501 | |
| dc.identifier.journal | International Journal of Psychiatry in Clinical Practice | es_ES |
| dc.identifier.other | https://hdl.handle.net/20.500.13003/19762 | |
| dc.identifier.pubmedID | 34543170 | es_ES |
| dc.identifier.pui | L2013743782 | |
| dc.identifier.scopus | 2-s2.0-85115205163 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12105/23349 | |
| dc.identifier.wos | 698226100001 | |
| dc.language.iso | eng | en |
| dc.publisher | Taylor & Francis | |
| dc.relation.publisherversion | https://dx.doi.org/10.1080/13651501.2021.1972120 | en |
| dc.rights.accessRights | open access | en |
| dc.rights.license | Attribution 4.0 International | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
| dc.subject | Major depressive disorder | |
| dc.subject | Sick leave | |
| dc.subject | Antidepressants | |
| dc.subject | Therapeutic approach | |
| dc.subject | Real world evidence | |
| dc.subject.decs | Antidepresivos | * |
| dc.subject.decs | Trastorno Depresivo Mayor | * |
| dc.subject.decs | Humanos | * |
| dc.subject.decs | Persona de Mediana Edad | * |
| dc.subject.decs | Adulto Joven | * |
| dc.subject.decs | Ausencia por Enfermedad | * |
| dc.subject.decs | Alemania | * |
| dc.subject.decs | Estudios Retrospectivos | * |
| dc.subject.decs | Adulto | * |
| dc.subject.decs | Medicina General | * |
| dc.subject.mesh | Sick Leave | * |
| dc.subject.mesh | General Practice | * |
| dc.subject.mesh | Depressive Disorder, Major | * |
| dc.subject.mesh | Young Adult | * |
| dc.subject.mesh | Adult | * |
| dc.subject.mesh | Germany | * |
| dc.subject.mesh | Antidepressive Agents | * |
| dc.subject.mesh | Humans | * |
| dc.subject.mesh | Middle Aged | * |
| dc.subject.mesh | Retrospective Studies | * |
| dc.title | Predictors of sick leave days in patients affected by major depressive disorder receiving antidepressant treatment in general practice setting in Germany | en |
| dc.type | research article | en |
| dspace.entity.type | Publication | |
| relation.isPublisherOfPublication | af7833ee-b4f1-4914-9339-d65cbe8472b9 | |
| relation.isPublisherOfPublication.latestForDiscovery | af7833ee-b4f1-4914-9339-d65cbe8472b9 |


